• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elite Pharma Inc (OP: ELTP )

0.5014 +0.0584 (+13.18%)
Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Elite Pharma Inc

< Previous 1 2 Next >
Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health
October 10, 2024
Northvale, New Jersey--(Newsfile Corp. - October 10, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Exposures Product Safety
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets
October 07, 2024
Northvale, New Jersey--(Newsfile Corp. - October 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company... 
Via Newsfile
Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
August 27, 2024
Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information
August 14, 2024
Northvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
February 14, 2024
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
November 14, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024
August 09, 2024
Northvale, New Jersey--(Newsfile Corp. - August 9, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information
July 01, 2024
Northvale, New Jersey--(Newsfile Corp. - July 1, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024
June 26, 2024
Northvale, New Jersey--(Newsfile Corp. - June 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Exposures Product Safety
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
May 20, 2024
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
August 14, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
August 09, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information
June 29, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2023 Financial Results on June 30, 2023
June 22, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
February 08, 2024
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
December 26, 2023
Via ACCESSWIRE
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
December 12, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
November 10, 2023
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
September 25, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information
February 14, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023 Ended September 30, 2022 and Provides Conference Call Information
November 15, 2022
Via ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
November 02, 2022
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
September 07, 2023
Via ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
August 28, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer
May 03, 2023
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product
April 20, 2023
Via ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
February 07, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2023 ended June 30, 2022, and Provides Conference Call Information
August 15, 2022
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist
December 22, 2022
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2023 Financial Results on November 15, 2022
November 08, 2022
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap